R
Refoxy Pharma
Refoxy is a Pharmaceutical company discovering medicines to treat age-related diseases and extend the years of healthy living
About Refoxy Pharma
Refoxy Pharma is a pioneering pharmaceutical company focused on discovering and developing medicines to treat age-related diseases and extend healthy living years. The company operates in the biotechnology and pharmaceutical market, targeting a growing demographic of aging populations worldwide. Refoxy's primary clients include healthcare providers, medical researchers, and patients suffering from age-related conditions.
The core of Refoxy's innovation lies in its research on FOXO proteins, a type of protein known as transcription factors. These proteins bind to specific DNA sequences and control the expression of genes, which can influence various biological processes such as stress resistance, metabolism, and longevity. By enhancing the function of FOXO proteins, Refoxy aims to develop therapeutic medicines that can repair, restore, and rejuvenate the body's natural functions, thereby improving healthspan—the period of life spent in good health.
Refoxy's business model revolves around extensive scientific research and development (R&D) to create novel drugs. The company invests heavily in understanding the genetic and environmental factors that influence aging. By leveraging this knowledge, Refoxy designs interventions that can modulate these factors to promote longer, healthier lives. The company generates revenue through the sale of its pharmaceutical products, licensing its technologies to other biotech firms, and forming strategic partnerships with healthcare organizations.
In summary, Refoxy Pharma is at the forefront of age-related disease treatment, using cutting-edge genetic research to develop medicines that enhance longevity and improve quality of life.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cologne, Germany
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 79.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, EIT Health, Longevity, proteomics, DT and LS, KoelnBusiness, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Dec 2024 | $10M | $40M | HTGF · NRW.BANK · Apollo Health Ventures · Boehringer Ingelheim Venture Fund | ↗ |
| SUPPORT PROGRAMOther financing | Jan 2023 | $0 | — | EIT Health | — |
Growth signals
Latest recorded traffic for Refoxy Pharma is 980 monthly website visits, up 58.1% over the last three months. Refoxy Pharma's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Boehringer Ingelheim Venture Fund
HTGF
NRW.BANK
Apollo Health Ventures
Other known investors1 additional known investor
EIT Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Refoxy Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Refoxy Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







